Cerdulatinib, with dual inhibition of JAK and SYK pathways, not only exhibited efficacy in controlling r/r CTCL and r/r PTCL but also provided rapid relief from pruritus, addressing one of the most distressing symptoms for CTCL patients [36]. This evidence concerns the gene SYK and primary cutaneous T-cell non-Hodgkin lymphoma.